Trinity Biotech (TRIB) has released an update.
Trinity Biotech plc, a biotechnology company specializing in diagnostics and diabetes management, has seen a surge in orders for its TrinScreen HIV product, pushing the anticipated 2024 sales to over $8 million. This increase comes as the company successfully scales up production to meet the rising demand for its rapid HIV tests. The company’s expansion into the wearable biosensor market highlights its commitment to innovation and growth within the biotech industry.
For further insights into TRIB stock, check out TipRanks’ Stock Analysis page.
